Mark E. Burkard, MD, PhD

  • Medical Oncology
Mark E. Burkard, MD, PhD

About

Dr. Mark Burkard is a professor of medicine and oncology at the University of Wisconsin School of Medicine and Public Health, Division of Hematology, Medical Oncology and Palliative care and is a member of the UW Health Breast Center.

His clinical specialties focus on breast cancer treatment, genomic instability, and precision oncology.

Dr. Burkard completed his PhD in chemistry from the University of Rochester, New York, earned his medical degree from the University of Rochester School of Medicine, Rochester, NY and completed a fellowship at Memorial Sloan-Kettering Cancer Center, New York, NY.

His research focuses on understanding the drivers of genomic changes in breast cancer and developing precision treatments. He is also studying how some patients are able to live many years with metastatic breast cancer. His laboratory seeks to advance cancer therapy by identifying person-to-person differences in cancer behavior and using this knowledge to select the best treatment.

Languages spoken
  • English
University affiliation
  • Department of Medicine

Practice locations

  • UW Carbone Cancer Center - Medical Oncology
    • 600 Highland Ave. / Madison, WI
    • (608) 265-1700
    • Closed now
    •  
      View hours, services and more
  • UW Carbone Cancer Center - Breast Cancer Clinic
    • 600 Highland Ave. / Madison, WI
    • (608) 266-6400
    • Closed now
    •  
      View hours, services and more
  • University Hospital - Breast Center
    • 600 Highland Ave. / Madison, WI
    • (608) 266-6400
    • Closed now
    •  
      View hours, services and more

Education & credentials

Board certifications
  • Medical Oncology
Medical School
  • University of Rochester School of Medicine, Rochester, NY
Fellowships
  • Memorial Sloan-Kettering Cancer Center, New York, NY

Specialties

Research and publications

Dr. Burkard is interested in targeted therapy directed at protein kinases. His laboratory seeks to link therapies with their targets within cancer cells using genetic tools, and to identify patients whose cancers are most likely to benefit from particular drugs. These studies will be used to inform clinical development of novel agents. Dr. Burkard is part of the breast cancer disease oriented working group.